Listen to your elders: why biopharma should be looking to small molecule experts for guidance

20 July 2018

It’s been a rapid journey for the biopharma industry over the last few years. We’ve seen the industry stagger to its feet – surpassing notable early setbacks caused by lack of control over hyperallergenic drugs, Rutger Oudejans, Brand Director, bioLIVE at UBM, observes in an Expert View article for The Pharma Letter.

But recent successes means biopharma is graduating. We’re seeing biopharmaceutical products succeed, with good efficacy rates, long-lasting reach and real patient impact. The pipeline is filled with next generation technologies.

In fact, the biopharma industry is predicted to grow at an unprecedented rate over the next few years, with a CAGR of 8.5% between 2017 and 2023. Biopharma is graduating at the top of the class. Stunned by the magnitude of its success, will biopharma fall and stumble in the adult world? Or will biotech leaders acknowledge that someone has grown up before them: the small molecule industry?

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK